|
|
|
|
Muscular Dystrophy - An NGO's Crusade to Help the Society
Medindia spoke to Dr.Vishwanathan, DCH, MRCP, Ph. D (Pediatric Neurology) Consultant Pediatric Neurologist and Founder President, Muscular Dystrophy Association India, a project that has crossed cultures and borders in research and facilities...
|
|
|
Biotech Stock Alert for AVI BioPharma Inc. Issued by Beacon Equity
(GlobeNewswire via COMTEX News Network) -- BeaconEquity.com announces an investment report featuring biotech company AVI BioPharma Inc.(Nasdaq:AVII). The report includes financial, comparative and investment analyses, and pertinent industry information you...
|
|
|
BioMarin to Present at the Barclays Capital Global Healthcare Conference
NOVATO, Calif., March 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.(Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare...
|
|
|
Grass-roots initiative raises more than $20 million to advance MDA's lifesaving mission
The spirit of St.Patrick's Day is alive and well. The Muscular Dystrophy Association today announced that, with 92 percent of some 10,000 retail locations reporting, its 2010 Shamrocks Against Dystrophy fundraiser is the most successful...
|
|
|
Competitive bidding program for durable medical equipment: Myths and realities
Medicare has been touting the merits of the "competitive" bidding program for durable, or home medical equipment and services (HME) to convince Congress that the program is good for seniors.Unfortunately, proponents have conveyed misleading information and...
|
|
|
Scientists Discover Chemical That 'Protects' Hearts of Muscular Dystrophy Patients
Heart Disease News Font Size A chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients has been discovered by University of Minnesota Medical School scientists.The chemical, which Medical School...
|
|
|
BioMarin to Present at the Barclays Capital Global Healthcare Conference
NOVATO, Calif., March 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.(Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare...
|
|
|
BioMarin to Present at the Barclays Capital Global Healthcare Conference
NOVATO, Calif., March 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.(Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare...
|
|
|
BioMarin to Present at the Barclays Capital Global Healthcare
BioMarin Pharmaceutical Inc.today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare Conference in Miami on Wednesday, March 24, 2010 at 9:30 a.m.
|
|
|
BioMarin to Present at the Barclays Capital Global Healthcare Conference
NOVATO, Calif., March 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare Conference in...
|
|
|
BioMarin to Present at the Barclays Capital Global Healthcare Conference
NOVATO, Calif., March 17 /PRNewswire-FirstCall/ BioMarin Pharmaceutical Inc.(Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Barclays Capital Global Healthcare...
|
|
|
Discovery Of Chemical That May Protect Hearts Of Muscular Dystrophy Patients
Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients - a fatal and most common form of muscular dystrophy in children.
|
|
|
Medical News: Discovery Of Chemical That May Protect Hearts Of Muscular Dystrophy Patients
Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients - a fatal and most common form of muscular dystrophy in children.
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results
Duchenne Muscular Dystrophy (DMD) -- AVI showed impressive levels of new dystrophin expression in DMD patients in a Phase 1 trial evaluating intramuscular injection of AVI-4658, AVI's lead drug candidate with potential to treat DMD by skipping...
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results Financial Results and Corporate Update Conference Call ..
Duchenne Muscular Dystrophy (DMD) -- AVI showed impressive levels of new dystrophin expression in DMD patients in a Phase 1 trial evaluating intramuscular injection of AVI-4658, AVI's lead drug candidate with potential to treat DMD by skipping...
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results
Duchenne Muscular Dystrophy (DMD) -- AVI showed impressive levels of new dystrophin expression in DMD patients in a Phase 1 trial evaluating intramuscular injection of AVI-4658, AVI's lead drug candidate with potential to treat DMD by skipping...
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results
Companies mentioned in this article: AVI BioPharma, Inc.BOTHELL, WA -- (Marketwire) -- 03/16/10 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today reported financial results for the three and twelve months ending December 31, 2009...
|
|
|
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results
BOTHELL, WA -- 03/16/10 -- AVI BioPharma, Inc.(NASDAQ: AVII), a developer of RNA-based drugs, today reported financial results for the three and twelve months ending December 31, 2009. "We have achieved significant progress over the past year. Our DMD...
|
|
|
'Molecular band-aid' may help protect hearts of Duchenne muscular dystrophy patients
By administering a chemical called a 'molecular band-aid,' U of M researchers were able to prevent heart injury in dystrophic canines Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the...
|
|
|
AVI BioPharma reports 4Q profit on warrants
BOTHELL, Wash.(AP) -- RNA drug developer AVI BioPharma Inc. reported a fourth-quarter profit Tuesday on a gain from the sale of warrants issued to buy shares of stock.AVI earned $3.5 million, or 3 cents per share, compared with a loss of $1.1 million, or 1...
|
|
|
AVI BioPharma reports 4Q profit on warrants
RNA drug developer AVI BioPharma Inc.reported a fourth-quarter profit Tuesday on a gain from the sale of warrants issued to buy shares of stock. AVI earned $3.5 million, or 3 cents per share, compared with a loss of $1.1 million, or 1 cent per share, a...
|
|
|
AVI BioPharma reports 4Q profit on warrants
BOTHELL, Wash.RNA drug developer AVI BioPharma Inc. reported a fourth-quarter profit Tuesday on a gain from the sale of warrants issued to buy shares of stock. AVI earned $3.5 million, or 3 cents per share, compared with a loss of $1.1 million, or 1 cent...
|
|
|
Researchers discover chemical that may protect hearts of muscular dystrophy patients
Researchers at the Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients a fatal and most common form of muscular dystrophy in children.The chemical, which Medical...
|
|
|
JCI online early table of contents: March 15, 2010
EDITOR'S PICK: Targeted gene therapy beneficial to mice with spinal muscular atrophy Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive muscle wasting and weakness.The severity of the disease varies between...
|
|
|
Research and Markets: Muscular Dystrophy - Drug Pipeline Analysis and Market Forecasts to 2016
DUBLINResearch and Markets (http://www.researchandmarkets.com/research/0166e2/muscular_dystrophy) has announced the addition of GlobalData 's new report "" to their offering.The report provides the key data, information and analysis on the global muscular...
|
